Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Hoggatt J, Tate TA, Pelus LM. Int J Nanomed. 2015;10:2647–2652.In this article, Lipegfilgrastim was referred to as a "long-acting biosimilar filgrastim". The term "biosimilar" was used too broadly in this case, as Lipegfilgrastim was not approved under t...
Guardado en:
Autores principales: | Hoggatt J, Tate TA, Pelus LM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c6fde9992f154241970ca9e958d79a30 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
por: Hoggatt J, et al.
Publicado: (2015) -
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia R, et al.
Publicado: (2016) -
Review on lipegfilgrastim
por: Gasparic M, et al.
Publicado: (2015) -
Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli D, et al.
Publicado: (2016) -
Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
por: Keohane C, et al.
Publicado: (2013)